Medios AG is a leading provider of Specialty Pharma solutions in Germany, specializing in the supply of high-priced medications for rare and chronic diseases such as oncology, neurology, autoimmunolog... Medios AG is a leading provider of Specialty Pharma solutions in Germany, specializing in the supply of high-priced medications for rare and chronic diseases such as oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia. The company operates through two primary segments: Pharmaceutical Supply, which distributes over 1,000 specialized products to pharmacies, medical specialists, and hospitals with temperature-controlled logistics from -80°C to +25°C; and Patient-Specific Therapies, a GMP-certified service producing around 400,000 individualized preparations annually, including cytostatic infusions, antibody therapies, virostatics, antibiotics, parenteral nutrition, and investigational medicinal products for clinical trials. Founded in 2015 and headquartered in Berlin, Medios AG emphasizes innovation in individualized medicine, utilizing state-of-the-art cleanrooms (classes A–D) and advanced analytical methods like NIR spectroscopy for drug authenticity. With seven manufacturing sites and four supply centers across nine locations, it ensures rapid, reliable access to therapies, fostering partnerships across Europe to optimize patient care for complex disorders. Medios AG plays a pivotal role in the Specialty Pharma market by bridging supply chain gaps and advancing precision pharmacotherapies.
We have not yet reviewed Medios's disclosures for Climate Targets data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.